Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

By sjmartinez • May 30, 2025

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik A, Mbanya Z, Dent R. Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. ESMO Open. 2025 May;10(5):105082. doi: 10.1016/j.esmoop.2025.105082. Epub 2025 May 15. PMID: 40441802.

Tags: Hematology/Oncology, HER2-low, metastatic breast cancer, patient-reported outcomes, Publications, Quality of Life, trastuzumab deruxtecan

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]

Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology

Yang H, Ribas A. Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology. J Thorac Oncol. 2025 Nov;20(11):1565-1568. doi: 10.1016/j.jtho.2025.08.009. PMID: 41203378.